Biological and Environmental Research Ontology

Last uploaded: December 23, 2022
Jump to:
Id http://purl.obolibrary.org/obo/NCIT_C82386
http://purl.obolibrary.org/obo/NCIT_C82386
Preferred Name

Dabrafenib
Definitions
An orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.
Type http://www.w3.org/2002/07/owl#Class

All Properties

definition

An orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.
label
Dabrafenib
prefLabel
Dabrafenib
Legacy Concept Name
BRAF_Inhibitor_GSK2118436
in_subset
Preferred_Name
Dabrafenib
Is_Value_For_GDC_Property
Chemical_Formula
C23H20F3N5O2S2
Display_Name
Dabrafenib
Maps_To
Dabrafenib
PDQ_Open_Trial_Search_ID
641977
UMLS_CUI
C3467876
FDA_UNII_Code
QGP4HA4G1B
prefixIRI
NCIT:C82386
Accepted_Therapeutic_Use_For
metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation
NCI_Drug_Dictionary_ID
641977
Contributing_Source
CTRP
FDA
subClassOf
code
C82386
type
PDQ_Closed_Trial_Search_ID
641977
Semantic_Type
Pharmacologic Substance
CAS_Registry
1195765-45-7
Add comment
Add proposal
Delete Subject Author Type Created
No notes to display